1 of study treatment, and therefore was not a
treatment-emergent adverse event).
2 Safety assessments included
treatment-emergent adverse events.
3 al sign changes, soft-tissue anesthesia, and
treatment-emergent adverse events.
4 oints included the frequency and severity of
treatment-emergent adverse events.
5 as no apparent dose-response relationship in
treatment-emergent adverse events.
6 ent-emergent serious adverse events, and all
treatment-emergent adverse events.
7 lerated, with few significant differences in
treatment-emergent adverse events.
8 ceived adalimumab plus methotrexate reported
treatment-emergent adverse events.
9 37%; no grade 3 or 4) being the most common
treatment-emergent adverse events.
10 and dizziness were the most common (>/=20%)
treatment-emergent adverse events.
11 (69%) and nausea (49%) were the most common
treatment-emergent adverse events.
12 , the proportion of patients who experienced
treatment-emergent adverse events (
79% [1125 of 1432 pat
13 Most patients experienced at least one
treatment-emergent adverse event (
87.8% in AZD9773-treat
14 The most common grade 3-4
treatment-emergent adverse events across all doses were
15 We analyzed
treatment-emergent adverse events (
AEs) and laboratory a
16 Safety assessment included recording of
treatment-emergent adverse events (
AEs) and serious AEs.
17 The most common
treatment-emergent adverse events (
AEs) in patients acro
18 The proportion of patients with >/= 1
treatment-emergent adverse events (
AEs) was similar acro
19 Overall incidence of
treatment-emergent adverse events (
AEs) was similar betw
20 All
treatment-emergent adverse events (
AEs) were recorded an
21 Treatment-emergent adverse events (
AEs), muscle-related
22 Treatment-emergent adverse events and laboratory abnorma
23 43 (10%) taking carbamazepine-CR had serious
treatment-emergent adverse events,
and 47 (11%) and 69 (
24 For our analysis, rates of SVR12,
treatment-emergent adverse events,
and graded laboratory
25 seven patients (42%) experienced grade >/= 3
treatment-emergent adverse events,
and one dose-limiting
26 lation time (RCT), retinal blood flow (RBF),
treatment-emergent adverse events,
and other safety para
27 ents treated with pravastatin (70%) reported
treatment-emergent adverse events,
and these caused stud
28 ho received Nexvax2 150 mug had at least one
treatment-emergent adverse event,
as did all three (100%
29 ho received Nexvax2 300 mug had at least one
treatment-emergent adverse event,
as did six (86%) of se
30 of 106 patients in the eliglustat group had
treatment-emergent adverse events,
as did 42 (79%) of 53
31 e most frequently reported treatment-related
treatment-emergent adverse events being fatigue, constip
32 l or allergic reactions and no difference in
treatment-emergent adverse events between the groups (64
33 Proportions of patients with
treatment-emergent adverse events by system organ class
34 mg groups, respectively) withdrew because of
treatment-emergent adverse events compared with nine (15
35 uded in the safety analysis had at least one
treatment-emergent adverse event deemed to be related to
36 rred in 523 (75%) of 696 patients; any-grade
treatment-emergent adverse events deemed to be related t
37 Treatment-emergent adverse events did not differ between
38 Incidence of
treatment-emergent adverse events did not differ between
39 e), but the proportion of patients reporting
treatment-emergent adverse events did not differ from pl
40 Myalgia was the most common
treatment-emergent adverse event during the study, occur
41 Treatment-emergent adverse events (
eg, insomnia, akathis
42 Serious
treatment-emergent adverse events (
excluding neoplasm pr
43 One patient (<1%) had a grade 3
treatment-emergent adverse event (
fatigue); no patients
44 The most common
treatment-emergent adverse event for brexpiprazole was a
45 The most common grade 3 or 4
treatment-emergent adverse event in each treatment group
46 The most common grade 3 or 4
treatment-emergent adverse event in patients allocated l
47 We noted
treatment-emergent adverse events in 613 (98%) of 627 pa
48 The most common
treatment-emergent adverse events in all 32 patients wer
49 Grade >/= 3
treatment-emergent adverse events in the amrubicin and t
50 Overall, 32 patients reported 56
treatment-emergent adverse events in the EMA401 group co
51 The most commonly reported treatment-related
treatment-emergent adverse events in the rolapitant vers
52 The incidence of
treatment-emergent adverse events in the safety populati
53 43 (10%) of 155
treatment-emergent adverse events in the solithromycin g
54 The most frequent
treatment-emergent adverse events in the sorafenib group
55 The most common
treatment-emergent adverse events (
incidence >10%) occur
56 The most common
treatment-emergent adverse events included hyperphosphat
57 Treatment-emergent adverse events included sedation, cha
58 to-moderate XR-NTX injection site reactions,
treatment-emergent adverse events including overdose did
59 The incidence of
treatment-emergent adverse events,
including infections
60 ne patient in the placebo group had a severe
treatment-emergent adverse event (
insomnia).
61 One
treatment-emergent adverse event leading to withdrawal f
62 Treatment-emergent adverse events leading to death occur
63 Treatment-emergent adverse events leading to discontinua
64 (80%) of 61 patients given placebo reported
treatment-emergent adverse events;
nasopharyngitis was t
65 ts in the clinical management group reported
treatment-emergent adverse events;
no treatment-related
66 The
treatment-emergent adverse events observed were generall
67 Treatment-emergent adverse events occurred in 136 (50%)
68 Treatment-emergent adverse events occurred in 20.1% of t
69 Treatment-emergent adverse events occurred in 224 (99%)
70 71 severe
treatment-emergent adverse events occurred in 25 (27%) p
71 Treatment-emergent adverse events occurred in 277 (72%)
72 Any-grade
treatment-emergent adverse events occurred in 523 (75%)
73 Treatment-emergent adverse events occurred in 62.3% of p
74 Local
treatment-emergent adverse events occurred in 7 patients
75 ipants given the MTD, eight gastrointestinal
treatment-emergent adverse events occurred in four (50%)
76 Treatment-emergent adverse events occurred in ten (63%)
77 The most common
treatment-emergent adverse events occurring in >10% of p
78 Treatment-emergent adverse events occurring significantl
79 Nine patients had a
treatment-emergent adverse event of grade 3 or higher, m
80 The most common
treatment-emergent adverse events of any grade were diar
81 Treatment-emergent adverse events of grade 3 or higher i
82 Treatment-emergent adverse events of grade 3 or worse oc
83 nd 21 (15%) in the placebo group had serious
treatment emergent adverse events (
p=0.63).
84 le and 255 [98%] receiving voriconazole) had
treatment-emergent adverse events (
p=0.122); the most co
85 e not associated with an increase in overall
treatment-emergent adverse event rates or neurocognitive
86 The most frequently reported
treatment-emergent adverse events,
regardless of causali
87 ed than temsirolimus, with grade 3 or higher
treatment-emergent adverse events reported for 94 (68%)
88 treatment-related, and no treatment-related
treatment-emergent adverse event resulted in death.
89 treatment related, and no treatment-related
treatment-emergent adverse events resulted in death.
90 n antidepressant reported significantly more
treatment-emergent adverse events (
RR, 1.07; 95% CI, 1.0
91 The primary outcome of the TAUSSIG study was
treatment-emergent adverse events;
secondary outcomes we
92 Treatment-emergent adverse events (
TEAEs) in each cohort
93 In both studies,
treatment-emergent adverse events (
TEAEs) reported by 10
94 Treatment-emergent adverse events (
TEAEs) were recorded.
95 Ocular and treatment-related
treatment-emergent adverse events (
TEAEs) were reported
96 Only a minority of patients (6.1%) reported
treatment-emergent adverse events (
TEAEs), all of which
97 ded the BRIEF-A Informant Report, MADRS, and
treatment-emergent adverse events (
TEAEs).
98 d percentage of responders by age strata and
treatment-emergent adverse events (
TEAEs).
99 The distribution of
treatment-emergent adverse events that led to study disc
100 and 47 (11%) and 69 (16%), respectively, had
treatment-emergent adverse events that led to withdrawal
101 Vomiting, nausea, and headache were the only
treatment-emergent adverse events that occurred in at le
102 The most commonly reported
treatment-emergent adverse events up to week 25 were gyn
103 patients in the CT-P6 group reported serious
treatment-emergent adverse events versus 22 (8%) of 278
104 Safety assessments included
treatment-emergent adverse events,
vital signs, and chan
105 At least one
treatment-emergent adverse event was experienced by 30-3
106 n acceptable safety profile; the most common
treatment-emergent adverse event was mild/moderate, typi
107 No serious
treatment-emergent adverse event was reported for more t
108 The incidence of any
treatment-emergent adverse events was 58.7% for the plac
109 Incidence of
treatment-emergent adverse events was similar across gro
110 Incidence of
treatment-emergent adverse events was similar between th
111 The incidence of
treatment-emergent adverse events was similar between th
112 The incidence of
treatment-emergent adverse events was similar in the pru
113 Incidence of
treatment-emergent adverse events was similar in the TAK
114 The most frequently reported
treatment-emergent adverse event were nasopharyngitis, i
115 Discontinuations due to
treatment-emergent adverse events were 10.3% and 27.8% o
116 Rates of grade 3 or 4
treatment-emergent adverse events were 41.2%, 60.1%, and
117 st common grade 3 or worse treatment-related
treatment-emergent adverse events were anaemia in 32 (5%
118 The most common grade 3 or worse
treatment-emergent adverse events were anaemia or decrea
119 Only two (mild/moderate)
treatment-emergent adverse events were considered relate
120 The most common
treatment-emergent adverse events were diarrhoea in the
121 Treatment-emergent adverse events were dose dependent.
122 The most commonly reported
treatment-emergent adverse events were dyspnea, cough, a
123 out rates did not differ between groups, and
treatment-emergent adverse events were evenly distribute
124 The most common
treatment-emergent adverse events were fatigue (48%), in
125 The most common
treatment-emergent adverse events were fatigue (62.0%) a
126 For these patients, the most common
treatment-emergent adverse events were fatigue or asthen
127 No severe
treatment-emergent adverse events were found.
128 (66 [64%] of 103 patients); the most common
treatment-emergent adverse events were headache (ten [10
129 The most common
treatment-emergent adverse events were headache, nausea,
130 Most frequent grade 3/4
treatment-emergent adverse events were hematologic (neut
131 In cohort III,
treatment-emergent adverse events were identical between
132 CYT003 was well tolerated; the most common
treatment-emergent adverse events were injection site re
133 Most
treatment-emergent adverse events were mild to moderate
134 aluren was generally well tolerated and most
treatment-emergent adverse events were mild to moderate
135 All
treatment-emergent adverse events were mild to moderate.
136 The most frequent
treatment-emergent adverse events were nausea (31.0%), c
137 The most common related grade 3 or 4
treatment-emergent adverse events were neutropenia, leuk
138 In the highest dose group, more
treatment-emergent adverse events were observed compared
139 Bosutinib had an acceptable safety profile;
treatment-emergent adverse events were primarily managea
140 A higher incidence of serious
treatment-emergent adverse events were recorded in patie
141 Treatment-emergent adverse events were reported at simil
142 Treatment-emergent adverse events were reported by 55 (8
143 Treatment-emergent adverse events were reported for 58 (
144 Treatment-emergent adverse events were reported in 103 p
145 Treatment-emergent adverse events were reported in 328 (
146 Treatment-emergent adverse events were reported in 60 (5
147 Serious
treatment-emergent adverse events were reported in 7% of
148 One or more
treatment-emergent adverse events were reported in 78% o
149 Moderate
treatment-emergent adverse events were reported in two p
150 Treatment-emergent adverse events were similar between g
151 Rates of
treatment-emergent adverse events were similar between g
152 The proportions of patients affected by
treatment-emergent adverse events were similar in the AL
153 The most common
treatment-emergent adverse events were somnolence (10.0%
154 No serious
treatment-emergent adverse events were treatment related
155 s well tolerated; 82 (77%) patients reported
treatment-emergent adverse events,
which were mostly min
156 Ocular
treatment-emergent adverse events,
while uncommon, appea
157 The only
treatment-emergent adverse event with a statistically si
158 disorders were the most frequently reported
treatment-emergent adverse events with both ceftazidime-
159 The primary end point was incidence of
treatment-emergent adverse events within 6 months.